Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Manage a positive pregnancy test with no pregnancy seen on ultrasound as a temporary high-risk state until location and outcome are established safely.
PUL describes what is not visible at one scan; it does not state where the pregnancy is. It occurs when urine or serum testing confirms pregnancy but a competent transvaginal scan does not show a definite intrauterine gestational sac or an ectopic pregnancy. The scan may simply be too early, the pregnancy may already be failing, or trophoblast may be implanted outside the uterine cavity. Explain this uncertainty directly without calling the pregnancy ectopic or miscarried prematurely.
Start with physiology and symptoms. Record pain site, onset and progression, bleeding, clots or tissue, shoulder-tip pain, dizziness, collapse, gastrointestinal or urinary symptoms and pregnancy intention. Measure observations and assess abdominal tenderness, guarding and pallor. Atypical presentations are common. Previous ectopic pregnancy, tubal surgery, pelvic infection, assisted conception, pregnancy with an IUD and smoking increase risk, but about one-third of ectopic pregnancies have no recognised risk factor.
Review the ultrasound with its context. Confirm that imaging was transvaginal, performed by someone trained in early-pregnancy diagnosis, and that uterus, both adnexa and the pelvis were examined. An empty uterus alone is not an ectopic diagnosis. Likewise, a small intrauterine fluid collection can be a pseudosac. A documented earlier intrauterine pregnancy changes interpretation of an apparently complete miscarriage; without that earlier proof, an empty uterus remains a PUL until follow-up resolves it.
Implantation may be normal but the gestational sac remains below ultrasound resolution, particularly with uncertain ovulation, irregular cycles or late conception.
An early intrauterine pregnancy may stop developing and pass before its location was ever documented, leaving positive hCG and an empty cavity.
Trophoblast implanted in a fallopian tube or another extrauterine site produces hCG without creating a definite intrauterine gestational sac.
Trophoblast begins hCG secretion before an intrauterine sac becomes consistently visible, creating a normal physiological interval of diagnostic uncertainty.
Failing or ectopic trophoblast often rises more slowly, plateaus or falls, but considerable overlap prevents any hCG curve from determining location.
Ectopic trophoblast erodes tubal tissue and vessels; bleeding can remain occult until distension or rupture causes intraperitoneal haemorrhage.
hCG may remain detectable for days or weeks after pregnancy tissue stops developing or passes, so biochemical resolution lags clinical events.
No visible pregnancy with a rise above 63% over 48 hours makes developing intrauterine pregnancy likely, but requires later imaging to prove location.
A decline above 50% over 48 hours suggests a pregnancy unlikely to continue and leads to a timed urine-test closure pathway.
A plateau, rise below 63% or fall below 50% leaves greater concern for ectopic or persisting trophoblast and needs review within 24 hours.
Worsening unilateral pain, shoulder-tip pain, syncope, peritonism or haemodynamic change requires emergency action even with a low or falling hCG.
An empty uterus after bleeding is not proof of completed intrauterine loss unless an earlier scan documented the pregnancy inside the uterus.
Normal implantation may simply precede ultrasound visibility and will later be demonstrated by appropriately timed repeat imaging.
Bleeding may have expelled an intrauterine pregnancy, but this diagnosis is secure only when earlier imaging proved its location or follow-up excludes ectopic.
Pain, abnormal hCG or adnexal findings may develop later, and rupture remains possible even while hCG falls.
Cervical, caesarean-scar, interstitial, ovarian or abdominal implantation can be missed if scanning focuses only on the fallopian tubes.
Unrecognised extrauterine pregnancy can rupture and cause rapid intraperitoneal bleeding, shock, emergency surgery, transfusion or death.
Using hCG alone to diagnose ectopic can expose an early viable intrauterine pregnancy to methotrexate or surgery.
Plateauing hCG may represent persisting PUL that requires further imaging, uterine assessment, methotrexate or surgery under specialist care.
Repeated tests, ambiguous language and prolonged uncertainty can intensify anxiety, grief and loss of trust even when the pregnancy resolves physically.
It protects against premature conclusions while obligating follow-up; it should disappear from the record only when location or resolution is established.
It may be genuinely too early or the pregnancy may be ectopic or already failing, so the same image can lead to very different outcomes.
Even a textbook rise cannot place trophoblast inside the uterus, and an abnormal trend cannot reveal whether tissue is tubal or intrauterine.
A new symptom invalidates a previously reassuring outpatient plan and requires fresh assessment independent of the next booked blood test.
Without a prior confirmed intrauterine pregnancy, disappearance after bleeding remains an unresolved location problem until hCG follow-up finishes.
Calling an empty uterus at one scan a miscarriage or ectopic pregnancy instead of a pregnancy of unknown location.
Using a single hCG value or discriminatory threshold to diagnose location or give methotrexate.
Reassuring from a rise above 63% without arranging ultrasound confirmation of location.
Assuming a falling hCG eliminates rupture risk and ignoring new pain or haemodynamic change.
Adding serum progesterone to distinguish ectopic from viable intrauterine pregnancy despite NICE advice.
Discharging without booked follow-up, written emergency advice, a 24-hour contact and active tracking of non-attendance.
Your practice draft is saved in this browser.
A stable patient with a pregnancy of unknown location has serum hCG 1,000 IU/L and 48 hours later 1,400 IU/L. She has mild unchanged discomfort. What does NICE recommend next?
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
NICE uses two serum hCG samples as near as possible to 48 hours apart, but not sooner. hCG describes trophoblastic activity rather than anatomical location. A rise above 63% makes a developing intrauterine pregnancy likely, yet ectopic remains possible. Plan repeat transvaginal ultrasound in 7–14 days, considering an earlier scan once hCG reaches at least 1,500 IU/L. If that scan still does not show a viable intrauterine pregnancy, arrange immediate senior review.
A decline above 50% over 48 hours means the pregnancy is unlikely to continue, but its previous location may remain unknown. Provide loss support and a urine pregnancy test 14 days after the second serum result. A negative test closes follow-up in an asymptomatic patient; a positive test requires early-pregnancy review within 24 hours. Persisting symptoms override this low-risk biochemical branch.
The indeterminate middle group is a fall below 50% or rise below 63%. This includes plateauing hCG and is associated with ectopic or persisting trophoblast. NICE recommends early-pregnancy clinical review within 24 hours rather than an automatic third blood test. A senior clinician integrates symptoms, examination, hCG, scan quality, pregnancy intention and potential treatment. Serum progesterone should not be added to distinguish ectopic from intrauterine pregnancy.
Do not apply a discriminatory zone as a treatment trigger. Above a chosen hCG concentration, failure to see an intrauterine pregnancy increases concern but does not prove ectopic pregnancy; multiple gestation, timing error, scan quality and uterine pathology can change visibility. Methotrexate on the first visit is appropriate only after a definitive ectopic diagnosis and exclusion of a viable intrauterine pregnancy under NICE criteria, not simply because the uterus is empty at hCG 1,500 or 2,000.
Safe outpatient care depends on communication. Give written information that location remains unresolved, exact blood and scan appointments, a 24-hour number and emergency symptoms. Check language, transport, caring responsibilities and phone access. Ask how the patient wants a partner involved and respect confidentiality. Maintain follow-up until a definite intrauterine pregnancy, confirmed ectopic pregnancy or negative testing establishes resolution.